136 related articles for article (PubMed ID: 25643531)
1. Trends in statin consumption and cardiovascular mortality in Croatia 2004-2012.
Vojvodić Z; Stimac D
Coll Antropol; 2014 Dec; 38 Suppl 2():73-8. PubMed ID: 25643531
[TBL] [Abstract][Full Text] [Related]
2. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Bennie M; Godman B; Bishop I; Campbell S
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
5. Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
Martikainen JE; Saastamoinen LK; Korhonen MJ; Enlund H; Helin-Salmivaara A
Med Care; 2010 Sep; 48(9):761-6. PubMed ID: 20706164
[TBL] [Abstract][Full Text] [Related]
6. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
10. Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
Sakshaug S; Furu K; Karlstad Ø; Rønning M; Skurtveit S
Br J Clin Pharmacol; 2007 Oct; 64(4):476-81. PubMed ID: 17441934
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
[TBL] [Abstract][Full Text] [Related]
12. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
14. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
Fuksa L; Vocelka M; Vytrisalova M
Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
[TBL] [Abstract][Full Text] [Related]
15. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Weizel A; Sawicki PT
MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
[No Abstract] [Full Text] [Related]
16. Managed care trends in statin usage.
Bazalo GR
Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
[TBL] [Abstract][Full Text] [Related]
17. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
[TBL] [Abstract][Full Text] [Related]
18. Is initiation of atorvastatin for employees a good buy for employers?
Culler SD; Weintraub WS
Mayo Clin Proc; 2009 Dec; 84(12):1059-61. PubMed ID: 19955241
[No Abstract] [Full Text] [Related]
19. The pharmaco-economics of peri-operative statin therapy.
Biccard BM; Sear JW; Foëx P
Anaesthesia; 2005 Nov; 60(11):1059-63. PubMed ID: 16229688
[TBL] [Abstract][Full Text] [Related]
20. Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Chaiyakunapruk N; Asuphol O; Dhippayom T; Poowaruttanawiwit P; Jeanpeerapong N
Int J Pharm Pract; 2011 Apr; 19(2):129-35. PubMed ID: 21385244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
